BrightGene Bio-Medical Hits Day High with 4.66% Surge in Stock Price

BrightGene Bio-Medical Technology Co., Ltd. has experienced a notable increase of 4.66% on June 29, 2026, reaching an intraday high of CNY 36.69. This performance stands in contrast to the China Shanghai Composite, which rose by 1.16% on the same day. Despite this positive movement, BrightGene's longer-term performance metrics reveal a more complex picture. Over the past month, the stock has declined by 30.57%, and its year-to-date performance shows a decrease of 26.7%. The company has faced challenges, with a net profit decline of 65.94% and a significant drop in operating cash flow, which is currently at its lowest level of CNY 210.71 million. BrightGene operates within the Pharmaceuticals & Biotechnology sector and holds a market capitalization of CNY 18,589 million. The company's financial indicators include a high price-to-earnings ratio of 510.00 and a return on equity of 1.44%. While the stock has shown some intraday gains, the overall financial landscape suggests ongoing difficulties for the company.